Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina
Departamento
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicacións en colaboración con investigadores/as de AstraZeneca (United Kingdom) (10)
2024
-
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
PharmacoEconomics - Open, Vol. 8, Núm. 6, pp. 887-896
2023
-
Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design – A population-based study
Revista Portuguesa de Cardiologia, Vol. 42, Núm. 12, pp. 985-995
2021
-
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
The Lancet Respiratory Medicine, Vol. 9, Núm. 3, pp. 260-274
2020
-
Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines
British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1034-1051
2019
2016
-
Prevalence and Perception of 24-Hour Symptom Patterns in Patients With Stable Chronic Obstructive Pulmonary Disease in Spain
Archivos de Bronconeumologia, Vol. 52, Núm. 6, pp. 308-315
2012
-
Factors associated with health-related quality of life in adults with asthma. A cross-sectional study
Multidisciplinary Respiratory Medicine, Vol. 7, Núm. 5
2011
-
Factors associated with a higher prevalence of work disability among asthmatic patients
Journal of Asthma, Vol. 48, Núm. 2, pp. 194-199
2010
-
Factors associated with asthma control in primary care patients: The CHAS study
Archivos de Bronconeumologia, Vol. 46, Núm. 7, pp. 358-363
2009
-
Inflammatory activation and left ventricular mass in essential hypertension
American Journal of Hypertension, Vol. 22, Núm. 4, pp. 444-450